Metraipolis › archive › dc_034e21d3d633
Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management — Europe PMC PMID:41270831
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41270831
- DOI
- 10.1016/j.molmet.2025.102287
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T10:27:30.538Z
- SHA-256 of the archived text
e2f4b9de2d25763e645b965e504498fa3ace172a3c9c5a4e2a2416b966d775b6- Stable URL of this page
https://metraipolis.com/documento/dc_034e21d3d633
How to cite
Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management — Europe PMC PMID:41270831 — Europe PMC (en), https://europepmc.org/article/MED/41270831 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_034e21d3d633 (Metraipolis archive dc_034e21d3d633, sha256 e2f4b9de2d25763e645b965e504498fa3ace172a3c9c5a4e2a2416b966d775b6)
BibTeX
@misc{dc034e21d3d633,
title = {Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management — Europe PMC PMID:41270831},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41270831},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_034e21d3d633; sha256 e2f4b9de2d25763e645b965e504498fa3ace172a3c9c5a4e2a2416b966d775b6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41270831. Agents can read the archived copy with the MCP tool read_document.